Management of pure metastatic teratoma in chemotherapy naïve testis cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16043-e16043
Author(s):  
Shahid Sattar Ahmed ◽  
Joseph Jacob ◽  
Clint Cary ◽  
Richard Foster ◽  
Lawrence H. Einhorn

e16043 Background: Management of metastatic testicular cancer often requires post-chemotherapy resection of teratoma. This is well known and described in literature. However, the ability of teratoma to metastasize independently is not as well appreciated, making chemotherapy futile in patients with pure metastatic teratoma. Methods: 15 patients with metastatic teratoma were identified of which 13 had only teratoma in the orchiectomy and 2 had predominantly teratoma. All 15 had normal serum hCG and AFP. Cases were derived from a retrospective review of patients seen from 1989-2016. Results: Mean age of patients was 27 years. 12 patients presented initially with Stage II disease and 2 presented with stage III disease. Median RP mass size was 6 cm with a range of 1.5-24 cm. 2 of 15 patients were treated initially with a single course of chemotherapy with BEP and showed no response. The remaining 13 patients only received resection(s). All 15 patients underwent RPLND with 2 patients requiring additional mediastinal and retrocrural resection and 1 requiring lobectomy. All surgical specimens showed pure teratoma on pathology with no other active germ cells. Patients were followed for a median duration of 5 years and all 15 remain with no evidence of disease at most recent follow up. However, 1 patient needed subsequent surgery for a late relapse of teratoma and 1 patient had a second extra-gonadal primary. Conclusions: Teratoma can metastasize in the absence of other germ cells. Surgical treatment alone for patients with pure metastatic teratoma of any stage can result in cure for the majority of patients and this approach can help avoid unnecessary chemotherapy.

1995 ◽  
Vol 13 (5) ◽  
pp. 1170-1176 ◽  
Author(s):  
J Baniel ◽  
R S Foster ◽  
R Gonin ◽  
J E Messemer ◽  
J P Donohue ◽  
...  

PURPOSE This study analyzed a large group of patients with testicular germ cell cancer in complete remission, who relapsed more than 2 years after completion of treatment. PATIENTS AND METHODS A review of all patients treated at Indiana University Medical Center from 1979 through 1992 for late relapse was conducted. Eighty-one patients were treated for late relapse of testicular cancer. Forty-seven patients relapsed more than 5 years after successful management of their initial disease. RESULTS At initial diagnosis, 35 patients had clinical stage I, 18 stage II, and 28 stage III disease. Twenty-three of 35 stage I, all 18 stage II, and all 28 stage III patients were treated by chemotherapy before their late relapse. The median follow-up duration of patients post-management of late relapse was 4.8 years. Twenty-one patients (25.9%) are continuously disease-free. Nineteen of these 21 patients had surgical resection of carcinoma or teratoma as a component of their therapy. Of sixty-five patients treated for late relapse by chemotherapy, 17 (26.2%) had a complete response, but only two have been continuously disease-free with chemotherapy alone. These two never received prior chemotherapy. CONCLUSION Late relapse of testis cancer is more common than previously thought. Surgery is the preferred mode of therapy. Chemotherapy has only modest success in this entity, in contrast to the excellent results in de novo germ cell tumors. Patients treated for testicular germ cell cancer need annual follow-up evaluations throughout their life due to the possibility of late relapse.


1991 ◽  
Vol 27 (6) ◽  
pp. 695-698 ◽  
Author(s):  
Rob L.H. Jansen ◽  
Richard Sylvester ◽  
Dirk T. Sleyfer ◽  
Wim W. ten Bokkel Huinink ◽  
Stan B. Kaye ◽  
...  

2008 ◽  
Vol 20 (9) ◽  
pp. 1627-1630 ◽  
Author(s):  
N. Murugaesu ◽  
T. Powles ◽  
J. Bestwick ◽  
R. T. D. Oliver ◽  
J. Shamash

2002 ◽  
Vol 9 (3) ◽  
pp. 154-160 ◽  
Author(s):  
YOSHIYUKI KAKEHI ◽  
TOSHIYUKI KAMOTO ◽  
MUTSUSHI KAWAKITA ◽  
OSAMU OGAWA

2013 ◽  
Vol 131 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Lisa G. van den Hengel ◽  
A.Q.M. Jeanne van Steijn-van Tol ◽  
Rogier M. Bertina ◽  
Henri H. Versteeg ◽  
Susanne Osanto

1989 ◽  
Vol 4 (1) ◽  
pp. 27-30 ◽  
Author(s):  
P. Lissoni ◽  
S. Crispino ◽  
S. Barni ◽  
G. Tancini

The role of prolactin (PRL) in testicular function and in its disorders is still obscure. To draw some preliminary conclusions on the relation between the PRL and testis cancer, we assessed the PRL response to thyrotropin-releasing hormone (THR) in 15 patients with testicular cancer (8 seminoma; 6 nonseminoma; 1 leydigioma), and in 11 healthy male subjects as controls. The results showed that 5/15 cancer patients gave no PRL response to TRH; 4 of them had a nonseminoma and the fifth a seminomatous testis carcinoma. Patients with nonseminoma had significantly lower mean peak values of PRL after TRH than controls or patients with seminoma. The biological significance of the altered PRL response to TRH in testicular carcinoma has still to be established.


2015 ◽  
Vol 2015 ◽  
pp. 1-4
Author(s):  
Kelly T. Harris ◽  
Shakil A. Shaikh ◽  
Mark W. Ball ◽  
Mohamad E. Allaf ◽  
Phillip M. Pierorazio

We present a patient with a metachronous, second testicular cancer after being diagnosed with pre-B cell ALL and receiving induction chemotherapy for a bone marrow transplant. We discuss the management of bilateral testis masses in a young patient with a hematologic malignancy as well as the role of immunosuppressive chemotherapy in developing a second cancer. This case illustrates the importance of recognizing bilateral testicular cancer early, as well as the importance of follow-up care in oncology patients including routine measurements of tumor markers. A multidisciplinary approach between medical oncology and urology, including close monitoring of the contralateral testis, remains paramount to patient care.


Onkologie ◽  
2013 ◽  
Vol 36 (4) ◽  
pp. 188-192 ◽  
Author(s):  
Carsten Rusner ◽  
Andreas Stang ◽  
Klaus-Peter Dieckmann ◽  
Heiko Friedel

Sign in / Sign up

Export Citation Format

Share Document